Broaden Horizons: The Advancement of Interstitial Cystitis/Bladder Pain Syndrome

por Li, Jin, Yi, Xianyanling, Ai, Jianzhong
Publicado 2022

Vitamin E intake and multiple health outcomes: an umbrella review

por Zhang, Tianyi, Yi, Xianyanling, Li, Jin, Zheng, Xiaonan, Xu, Hang, Liao, Dazhou, Ai, Jianzhong
Publicado 2023

Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine

por Zheng, Xiaonan, Xu, Hang, Yi, Xianyanling, Zhang, Tianyi, Wei, Qiang, Li, Hong, Ai, Jianzhong
Publicado 2021

Adjuvant chemoradiotherapy vs chemotherapy for resectable biliary tract cancer: a propensity score matching analysis based on the SEER database

por Zhu, Yueting, Liu, Xia, Lin, Yiyun, Tang, Liansha, Yi, Xianyanling, Xu, Hang, Yuan, Yunlong, Chen, Ye
Publicado 2023

Tumor antigens and immune subtypes guided mRNA vaccine development for kidney renal clear cell carcinoma

por Xu, Hang, Zheng, Xiaonan, Zhang, Shiyu, Yi, Xianyanling, Zhang, Tianyi, Wei, Qiang, Li, Hong, Ai, Jianzhong
Publicado 2021

Construction of PANoptosis signature: Novel target discovery for prostate cancer immunotherapy

por Yi, Xianyanling, Li, Jin, Zheng, Xiaonan, Xu, Hang, Liao, Dazhou, Zhang, Tianyi, Wei, Qiang, Li, Hong, Peng, Jiajie, Ai, Jianzhong
Publicado 2023

Association of Novel Androgen Receptor Axis-Targeted Therapies With Diarrhea in Patients With Prostate Cancer: A Bayesian Network Analysis

por Xiong, Xingyu, Xu, Hang, Wang, Sheng, Liao, Xinyang, Yi, Xianyanling, Jin, Kun, Lei, Haoran, Bai, Shengjiang, Qiu, Shi, Yang, Lu
Publicado 2022

IGFBP7 and the Tumor Immune Landscape: A Novel Target for Immunotherapy in Bladder Cancer

por Yi, Xianyanling, Zheng, Xiaonan, Xu, Hang, Li, Jin, Zhang, Tianyi, Ge, Peng, Liao, Dazhou, Li, Hong, Lyu, Xiaoyan, Ai, Jianzhong
Publicado 2022

Comparison of the Efficacy and Safety of Extracorporeal Shock Wave Lithotripsy and Flexible Ureteroscopy for Treatment of Urolithiasis in Horseshoe Kidney Patients: A Systematic Re...

por Yi, Xianyanling, Cao, Dehong, You, Pinghong, Xiong, Xingyu, Zheng, Xiaonan, Jin, Tao, Peng, Ge, Xu, Hang, Liao, Dazhou, Wei, Qiang, Li, Hong, Yang, Lu, Ai, Jianzhong
Publicado 2021

SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs

por Xu, Hang, Zhang, Jiapeng, Zheng, Xiaonan, Tan, Ping, Xiong, Xingyu, Yi, Xianyanling, Yang, Yang, Wang, Yan, Liao, Dazhou, Li, Hong, Wei, Qiang, Ai, Jianzhong, Yang, Lu
Publicado 2022